Clinical trials: First Pregnancy
Cervical Cancer, Cervical Intraepithelial Neoplasia
CASUS: Improved and Quality Assured Collection of First-void Urine
The goal of the overall CASUS project is to develop the first fully molecular integrated cervical cancer screening approach, based on first-void urine as an easily accessible and non-invasive source of biomarkers.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia, Human Papilloma Virus, HPV-Related Cervical Carcinoma
- Trial name
- CASUS-WP1 (NCT04480866)
- Testing
- Colli-Pee® (FV5000 and Small Volumes)
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- Universiteit Antwerpen
Ovarian Cancer
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
The purpose of this study is to compare the effectiveness (progression free survival) of the experimental combination of carboplatin + liposomal doxorubicin with the standard combination of carboplatin + paclitaxel in first line…
- Trial name
- NCT00326456
- Testing
- liposomal doxorubicin, carboplatin, paclitaxel
- Where
- 38 sites in Italy, Portugal and 1 more
- Volunteers
- 820 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Cancer, HER2
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Ovarian cancer exhibits the highest mortality rate among gynecological malignancies. Currently, the combination of paclitaxel and carboplatin remains the standard first-line chemotherapy regimen for neoadjuvant or postoperative…
- Trial name
- NCT07285941
- Testing
- RC48 + Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Cervical Cancer
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
- Trial name
- NCT04646005
- Testing
- Cemiplimab, ISA101b
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 113 people
- Sponsor
- Regeneron Pharmaceuticals
Renal Cell Carcinoma
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by…
- Trial name
- CLEAR (NCT02811861)
- Testing
- Lenvatinib, Everolimus, Pembrolizumab
- Where
- 183 sites in United States, Australia and 18 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Renal Cell Cancer, Metastatic Renal Cell Cancer
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.
- Trial name
- NCT01829841
- Testing
- Famitinib, Sunitinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Clear-cell Renal Cell Carcinoma, RCC
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
This is an open label, randomized phase II trial. Eligible subjects will be randomized in a 1:1 ratio and stratified for known prognostics variables to one of two first-line medication treatment arms.
- Conditions
- Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
- Trial name
- NCT03035630
- Testing
- Avelumab, Sunitinib
- Where
- United States
- Sponsor
- Guru Sonpavde
Renal Cell Carcinoma, Cardiotoxicity
A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)
While sunitinib can be very helpful to treat kidney cancer, these medications can also cause side effects, including heart damage.
- Conditions
- Renal Cell Carcinoma, Cardiotoxicity, Heart Failure, Hypertension
- Trial name
- SUPER (NCT01014065)
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer, Prostate Cancer
Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor).
- Conditions
- Breast Cancer, Prostate Cancer, Urinary Bladder Cancer
- Trial name
- NCT02139371
- Testing
- Injection of 64Cu-DOTA-AE105
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Urologic Cancer
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy
The study described here is being conducted to prospectively confirm the performance of the ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy and support of CE-marking the test for a…
- Trial name
- NCT04720599
- Testing
- ExoDx Prostate(IntelliScore)
- Where
- 3 sites in United States, Germany
- Volunteers
- 120 people
- Sponsor
- Exosome Diagnostics, Inc.
Bacterial Vaginosis
A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis
This was a two-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy (for Part B) of BNT331 in healthy women (Part A) and in women diagnosed…
- Trial name
- NCT06469164
- Testing
- BNT331
- Where
- 6 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Premature Birth
Implementation of the Golden Hour for Preterm Infants : a Quality Improvement Study
Effective initial stabilization of preterm neonates in the initial 60 minutes of life ("golden hour") was shown to improve outcomes.
- Trial name
- NCT05175911
- Testing
- golden hour : an initial standardized stabilization
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Preterm
PRETERM DELİVERY and MYOCINE BINDING PROTEIN C LEVELs
IT WAS AIMED TO EVALUATE IF MBPC CAN BE USED IN PREDICTION OF EARLY BIRTH. TAKING THE FIRST TRIMESTER FROM PREGNANCY WAS STORED UNTIL THE TIMING OF DELIVERY.THE PARTICIPANTS WERE SEPARATED INTO TWO GROUPS ACCORDING TO THE TIME OF…
- Trial name
- NCT05513768
- Testing
- level of myosin binding protein c in serum
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Gaziosmanpasa Research and Education Hospital
Metastatic Renal Cell Carcinoma
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on…
- Trial name
- SPAZO (NCT02282579)
- Testing
- Pazopanib
- Where
- 34 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
PREGNANCY
Induction Versus Expectant Management With Abnormal Maternal Biochemical Markers
Induction of labor at term versus expectant management among women with abnormal maternal biochemical markers. A randomized controlled trial
- Trial name
- NCT02754635
- Testing
- Induction of labour, Expectant management
- Where
- Israel
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Ovarian Cancer, Fallopian Tube Cancer
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
The purpose of this research study is to evaluate how patients with newly diagnosed advanced ovarian, fallopian tube, primary peritoneal cancer and papillary serous or clear cell mullerian tumors respond to consolidation therapy…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Papillary Serous Mullerian Tumor
- Trial name
- NCT00520013
- Testing
- bevacizumab, erlotinib, paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Pregnancy Related, Thyroid Stimulating; Hormone, C
Correlation Between Levothyroxine and Blood Th17/Treg in Pregnant Women With Normal-high TSH and Positive TPOAb
The purpose of this clinical trial is to understand the impact of different doses of levothyroxine on the immune inflammatory response in pregnant women with normal-high TSH and positive TPOAb in the first half of pregnancy.
- Trial name
- NCT06527859
- Testing
- Levothyroxin
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital of Zhengzhou University
First Trimester Pregnancy, Surgical Termination of Pregnancy
Misoprostol for Cervical Priming Prior to Vacuum Aspiration
Despite of the widespread use, and extensive studies, the optimal route of administration of misoprostol before surgical abortion remains to be defined.
- Trial name
- NCT01933360
- Testing
- Misoprostol sublingual, 1h, Misoprostol sublingual, 3h, Misoprostol vaginal, 1h
- Where
- Sweden
- Volunteers
- 184 people
- Sponsor
- Karolinska Institutet
IgA Nephropathy
Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis and one of the leading causes of end-stage renal disease in China.
- Trial name
- NCT05528991
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Shenzhen Second People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.